DexCom, Inc. $DXCM Shares Bought by GDS Wealth Management

Key Points

• GDS Wealth Management increased its stake in DexCom, Inc. by 9.2% in the first quarter, owning 174,711 shares valued at approximately $11.93 million.
• Analysts have mixed ratings on DexCom, with three ratings as Strong Buy, fifteen as Buy, and four as Hold, while the current consensus target price is $99.89.
• DexCom reported a 15.2% increase in revenue compared to the same quarter last year, with earnings per share of $0.48, surpassing estimates.

GDS Wealth Management lifted its position in DexCom, Inc. (NASDAQ:DXCM - Free Report) by 9.2% in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 174,711 shares of the medical device company's stock after purchasing an additional 14,714 shares during the quarter. GDS Wealth Management's holdings in DexCom were worth $11,931,000 at the end of the most recent reporting period.

A number of other institutional investors also recently bought and sold shares of the company. Golden State Wealth Management LLC grew its holdings in shares of DexCom by 211.2% during the 1st quarter. Golden State Wealth Management LLC now owns 389 shares of the medical device company's stock worth $27,000 after purchasing an additional 264 shares during the period. Zions Bancorporation National Association UT purchased a new position in DexCom during the first quarter worth about $27,000. Optiver Holding B.V. purchased a new position in DexCom during the fourth quarter worth about $33,000. Heck Capital Advisors LLC acquired a new stake in shares of DexCom during the fourth quarter valued at about $38,000. Finally, Alpine Bank Wealth Management purchased a new stake in shares of DexCom in the 1st quarter valued at approximately $40,000. 97.75% of the stock is owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other DexCom news, Director Mark G. Foletta sold 2,750 shares of DexCom stock in a transaction that occurred on Friday, August 15th. The stock was sold at an average price of $81.06, for a total transaction of $222,915.00. Following the transaction, the director owned 51,121 shares of the company's stock, valued at $4,143,868.26. The trade was a 5.10% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, EVP Michael Jon Brown sold 500 shares of the firm's stock in a transaction that occurred on Friday, August 15th. The stock was sold at an average price of $80.29, for a total transaction of $40,145.00. Following the transaction, the executive vice president owned 94,102 shares in the company, valued at approximately $7,555,449.58. This trade represents a 0.53% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders sold 21,906 shares of company stock valued at $1,832,451. 0.32% of the stock is owned by insiders.

DexCom Stock Down 5.7%

NASDAQ DXCM traded down $4.6750 on Monday, hitting $77.5850. 2,344,188 shares of the stock were exchanged, compared to its average volume of 3,867,210. DexCom, Inc. has a fifty-two week low of $57.52 and a fifty-two week high of $93.25. The company has a 50-day moving average price of $82.81 and a 200-day moving average price of $79.77. The company has a quick ratio of 1.35, a current ratio of 1.52 and a debt-to-equity ratio of 0.48. The company has a market cap of $30.42 billion, a PE ratio of 53.76, a PEG ratio of 1.72 and a beta of 1.43.

DexCom (NASDAQ:DXCM - Get Free Report) last released its quarterly earnings data on Wednesday, July 30th. The medical device company reported $0.48 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.45 by $0.03. The business had revenue of $1.16 billion during the quarter, compared to analysts' expectations of $1.13 billion. DexCom had a net margin of 13.29% and a return on equity of 30.41%. The company's revenue for the quarter was up 15.2% on a year-over-year basis. During the same period in the previous year, the company earned $0.43 EPS. DexCom has set its FY 2025 guidance at EPS. Sell-side analysts anticipate that DexCom, Inc. will post 2.03 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities analysts recently weighed in on DXCM shares. Citigroup reaffirmed a "buy" rating and set a $102.00 price objective (up previously from $82.00) on shares of DexCom in a research report on Thursday, May 22nd. Oppenheimer upped their price target on DexCom from $95.00 to $102.00 and gave the stock an "outperform" rating in a research note on Thursday, July 31st. Argus initiated coverage on DexCom in a research note on Thursday. They issued a "buy" rating and a $100.00 price objective for the company. Raymond James Financial boosted their price objective on DexCom from $99.00 to $102.00 and gave the company a "strong-buy" rating in a report on Thursday, July 31st. Finally, Barclays increased their target price on DexCom from $93.00 to $98.00 and gave the stock an "equal weight" rating in a research note on Wednesday, July 30th. Three equities research analysts have rated the stock with a Strong Buy rating, fifteen have given a Buy rating and four have issued a Hold rating to the stock. According to data from MarketBeat, DexCom has an average rating of "Moderate Buy" and an average target price of $99.89.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.